Type of medical product:

Protein based

Novelty:

Biosimilar

Field:

Autoimmune diseases

Indications for use:

Rheumatoid arthritis

Status:

Preclinical trials in vivo

Indications: Rheumatoid arthritis

This is a recombinant monoclonal antibody-based therapeutic for  treatment of rheumatoid arthritis.


Rheumatoid arthritis is a systemic connective tissue disorder  with predominant impairments in small joints of erosive-destructive polyarthritis of unknown origin with a complex autoimmune pathogenesis.

The causes of the  disease are still unknown . Indirect data, such as elevation in blood leukocyte count and erythrocyte sedimentation rate (ESR) indicates an infection-related origin of the disease. The disease is believed to be associated with infection causing immune disorders in genetically predisposed persons when so called immune complexes (of antibodies, viruses, etc.) are formed. The latter then accumulates in tissues and induces joint damage. The disease is characterized by a high disability rate (70%)  that develops  relatively early after the disease onset. The main death cause in these patients  are infectious complications and renal failure.